Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

BD Diagnostics and Bruker Collaborate to Improve Microbial Identification and Antimicrobial Susceptibility Testing

Published: Friday, February 11, 2011
Last Updated: Friday, February 11, 2011
Bookmark and Share
BD Diagnostics and Bruker Daltonics Inc. have announced an international co-development and co-marketing collaboration that will promote an emerging, integrated approach to bacterial and fungal identification and antimicrobial susceptibility testing.

Through this collaboration, identification of microorganisms will be performed with the Bruker MALDI Biotyper, a mass spectrometry-based proteomic “fingerprinting” system specifically configured for rapid identification of bacteria, yeast and fungi.  The MALDI Biotyper is available in a clinical version with IVD-CE mark in Europe and is for research use only (RUO) in the United States, where Bruker intends to seek FDA clearance.  

BD and Bruker intend to combine the MALDI Biotyper microbial ID system with automated antimicrobial susceptibility testing on the BD Phoenix™ Microbiology System.  The BD EpiCenter™ Microbiology Data Management System, which will manage patient data from both the identification and the susceptibility test systems, will facilitate this industry-first integrated approach.

The MALDI Biotyper – BD EpiCenter software integration will be further developed to optimize workflows for rapid MALDI Biotyper pathogen identification directly on positive blood cultures from the leading BD BACTECTM blood culture system.  This rapid blood culture-to-ID workflow is supported by Bruker’s new MALDI Sepsityper™ consumables kit, which today is for RUO.  It is expected to become clinically important in the future, as time-to-result for pathogen identification is critical to management of patients having potentially serious bloodstream infections or sepsis.

 “This collaboration is ideal because the competencies of the two organizations will complement each other by providing excellent microbiology solutions for the customer,” said Jamie Condie, Vice President and General Manager, Infectious Disease, BD Diagnostics – Diagnostic Systems. “We have chosen to collaborate with Bruker because we believe that its mass spectrometry technologies are the future of microbial identification, and that the MALDI Biotyper is the first and best solution to the market.  We expect this collaboration will result in enhanced clinical responsiveness while improving lab efficiency.”

“At Bruker, we are excited about this new strategic collaboration with BD because of the potential it holds to significantly advance clinical microbiology,” said Frank Laukien, Ph.D., President and CEO of Bruker Corporation.  “Working with a worldwide leader in microbiology and infectious disease will enable us to further expand the groundbreaking MALDI Biotyper molecular method for microbial ID to its full extent.”

Microbial identification and antimicrobial susceptibility testing is the end-point of the major work a microbiology lab performs on a daily basis.  After culturing and isolating bacteria and fungi from patient specimens, organisms need to be identified and tested to determine which drugs will inhibit or stop their growth.  The Bruker MALDI Biotyper allows highly accurate, rapid and cost-effective identification through a process in which organisms are identified by the unique spectrum of the major proteins and peptides that constitute their makeup.  The accuracy and benefits of the MALDI Biotyper have been well documented in over 30 peer-reviewed articles.  

Antimicrobial susceptibility testing is conducted via traditional automated systems such as the BD Phoenix System.  The combination of the two leading technologies, the BD Phoenix System and the MALDI Biotyper, and the data management through the BD EpiCenter System, will provide laboratorians with a groundbreaking new approach to identification and susceptibility testing, which will reduce the turnaround time for critical diagnostic results, while also improving laboratory efficiency and costs.  

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BD Receives FDA Clearance for Gastroenteritis Test
The FDA-cleared BD MAX™ Enteric Bacterial Panel for use on the BD MAX System.
Monday, May 12, 2014
BD Collaborates with CME Medical
Collaboration to increase coverage in the UK and Ireland and to provide expanded specialist support to its growing Saf-T-Intima™ customer base.
Sunday, January 12, 2014
BD Helps to Support the Implementation of New Sharps Instruments in Healthcare Regulations
Legislation in place to protect healthcare workers from sharps injuries as a result of new EU Directive on sharps injury prevention.
Thursday, June 13, 2013
New IVD Product is Designed to Improve Prevention and Control of GBS in Newborns
BD MAX™ GBS assay receives FDA clearance and CLIA moderate complexity test categorization.
Wednesday, March 28, 2012
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos